Stock Analysis
Poltreg (WSE:PTG) Full Year 2023 Results
Key Financial Results
- Net loss: zł13.6m (loss widened by zł11.6m from FY 2022).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Poltreg Earnings Insights
Looking ahead, revenue is forecast to grow 33% p.a. on average during the next 2 years, compared to a 18% growth forecast for the Biotechs industry in Europe.
Performance of the market in Poland.
The company's shares are down 7.8% from a week ago.
Risk Analysis
You still need to take note of risks, for example - Poltreg has 2 warning signs (and 1 which shouldn't be ignored) we think you should know about.
Valuation is complex, but we're helping make it simple.
Find out whether Poltreg is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:PTG
Poltreg
Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases.
Flawless balance sheet with high growth potential.
